Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Sangro B, Galle PR, Kelley RK, Charoentum C, De Toni EN, Ostapenko Y, Heo J, Cheng AL, Wilson Woods A, Gupta C, Abraham J, McCoy CL, Patel N, Negro A, Vogel A, Abou-Alfa GK.
Sangro B, et al. Among authors: heo j.
J Clin Oncol. 2024 May 28:JCO2301462. doi: 10.1200/JCO.23.01462. Online ahead of print.
J Clin Oncol. 2024.
PMID: 38805668